Laparoscopic splenectomy's effect on liver function in cirrhosis patients
The Effect of Laparoscopic Splenectomy on Liver Reserve Function for Cirrhosis Patients
This study tests if a minimally invasive surgery to remove the spleen can improve liver function in patients with cirrhosis.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Northern Jiangsu People's Hospital Academic / other |
| Locations | 1 site (Yangzhou, Jiangsu) |
| Trial ID | NCT05325424 on ClinicalTrials.gov |
What this trial studies
This study investigates the impact of laparoscopic splenectomy on liver reserve function in patients diagnosed with cirrhosis. Participants undergo the surgical procedure, and their liver function indicators are monitored at multiple time points post-surgery. The goal is to determine if this surgical intervention can enhance liver function and improve overall patient prognosis. A standardized treatment and follow-up plan is implemented to ensure consistency in patient care.
Who should consider this trial
Good fit: Ideal candidates include patients with cirrhosis and splenomegaly who have a platelet count below 50*10^9/L.
Not a fit: Patients with advanced liver disease (Child-Pugh grade C), malignancies, or other serious health conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve liver function and quality of life for patients with cirrhosis.
How similar studies have performed: While similar studies have explored the effects of splenectomy on liver function, this specific approach and its outcomes in cirrhosis patients are relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * A clinical, radiological or histologic diagnosis of cirrhosis of any etiology * Splenomegaly with secondary hypersplenism, Platelet count \< 50\*10\^9/L * Informed consent to participate in the study Exclusion Criteria: * Hepatocellular carcinoma or any other malignancy, * Child-Pugh grade C * Recent peptic ulcer disease * History of Hemorrhagic stroke * Pregnancy. * Uncontrolled Hypertension * Bleeding portal hypertension * Human immunodeficiency virus (HIV) infection
Where this trial is running
Yangzhou, Jiangsu
- Clinical Medical College of Yangzhou University — Yangzhou, Jiangsu, China (Recruiting)
Study contacts
- Study coordinator: Guo-Qing Jiang, MD
- Email: jgqing2003@hotmail.com
- Phone: +8651487373272
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.